FORT LEE, N.J., June 8 /PRNewswire-FirstCall/ -- Alpharma Inc. today announced that it had reached an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd (“Hisun”) that, over the next several years, will double the company’s capacity to manufacture one of its major active pharmaceutical ingredients (“API”), Vancomycin, subject to the receipt of the required regulatory approvals. Vancomycin is the treatment of choice for severe gram positive hospital infections. Alpharma is one of the worlds leading suppliers of Vancomycin, which is currently manufactured at Alpharma sites in Copenhagen, Denmark and Budapest, Hungary.
